Insider Selling: Illumina (NASDAQ:ILMN) SVP Sells 1,033 Shares

Illumina, Inc. (NASDAQ:ILMN) SVP Christensen Jakob Wedel sold 1,033 shares of Illumina stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $191.52, for a total value of $197,840.16. Following the completion of the transaction, the senior vice president directly owned 14,023 shares of the company’s stock, valued at $2,685,684.96. This represents a 6.86% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Illumina Price Performance

Shares of NASDAQ:ILMN traded up $8.24 during trading on Thursday, reaching $213.24. 3,249,831 shares of the company traded hands, compared to its average volume of 1,908,677. The firm has a market capitalization of $32.20 billion, a PE ratio of 39.78, a PEG ratio of 2.65 and a beta of 1.45. Illumina, Inc. has a 52 week low of $88.00 and a 52 week high of $220.32. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53. The company’s 50 day moving average is $185.90 and its two-hundred day moving average is $151.49.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, topping analysts’ consensus estimates of $1.23 by $0.08. The company had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.13 billion. Illumina had a return on equity of 29.84% and a net margin of 18.36%.Illumina’s revenue was up 9.4% on a year-over-year basis. During the same quarter last year, the business earned $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, sell-side analysts predict that Illumina, Inc. will post 5.36 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of ILMN. Kerrisdale Advisers LLC bought a new position in shares of Illumina in the second quarter worth about $3,883,000. Sigma Planning Corp bought a new stake in shares of Illumina during the 2nd quarter valued at approximately $642,000. Two Sigma Securities LLC acquired a new position in Illumina during the 2nd quarter worth approximately $362,000. Alyeska Investment Group L.P. increased its position in Illumina by 89.9% during the 2nd quarter. Alyeska Investment Group L.P. now owns 581,730 shares of the life sciences company’s stock worth $102,286,000 after purchasing an additional 275,363 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. lifted its stake in Illumina by 29.2% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 3,056 shares of the life sciences company’s stock valued at $537,000 after purchasing an additional 690 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have commented on ILMN shares. Deutsche Bank Aktiengesellschaft lowered shares of Illumina to a “hold” rating in a report on Wednesday, August 5th. Canaccord Genuity Group lifted their price objective on shares of Illumina from $190.00 to $205.00 and gave the company a “hold” rating in a research note on Monday, August 3rd. Evercore reissued an “outperform” rating on shares of Illumina in a research note on Monday, July 6th. Piper Sandler restated an “overweight” rating and set a $225.00 price objective (up from $200.00) on shares of Illumina in a research report on Monday, August 3rd. Finally, Guggenheim upped their target price on Illumina from $200.00 to $226.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $188.40.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.